Elucigene  CF29 has been developed to provide laboratories with a simple and accurate means of routinely testing 29 of the most prevalent mutations in individuals of European Caucasian descent. Genotype information for ΔF508 makes the test highly valuable in both disease diagnosis and screening applications.  Note that this product does not detect I148T.

Analysis of the polythymidine tract in intron 8 of the CFTR gene is of particular clinical significance when the R117H mutation is identified. Elucigene  CF Poly-T is separately available for the analysis of the polythymidine tract to allow total flexibility of choice for Poly-T testing in CF screening programs.

 
• How to Order   • Cat. No. PT003B2

Elucigene  CF30 has been developed and approved for routine use in the French national neonatal cystic fibrosis screening program. The panel of mutations detected by Elucigene  CF30 are identified as the thirty most frequent within the French population. Elucigene  CF30 is also relevant for screening other European populations, particularly those of Spanish and Scandinavian descent.

 
• How to Order   • Cat. No. CF030B1

 

Elucigene  CF7 is particularly useful for cystic fibrosis screening in the Ashkenazi Jewish community. The seven cystic fibrosis mutations detected by CF7 provide a coverage of approximately 97% and can be used alongside other gel-based kits specifically developed for genetic testing of nine other diseases common in Ashkenazi Jews.

 
• How to Order   • Cat. No. CF007B4

 

Elucigene  CF-MEP detects five mutations in the CFTR gene that are particularly common in Sephardic Jews of middle-eastern origin. When used together with Elucigene  CF7 a total of eleven different mutations can be identified giving an excellent coverage in Jews of various ethnic backgrounds.

 

• How to Order   • Cat. No. YF005B4